Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

COVA4231, a potent CD3/CD33 bispecific FynomAb with IgG-like pharmacokinetics for the treatment of acute myeloid leukemia.

Klupsch K, Baeriswyl V, Scholz R, Dannenberg J, Santimaria R, Senn D, Kage E, Zumsteg A, Attinger-Toller I, von der Bey U, König-Friedrich S, Dupuy F, Lembke W, Albani C, Wendelspiess S, Dinkel L, Saro D, Hepler RW, Laszlo GS, Gudgeon CJ, Bertschinger J, Brack S, Walter RB.

Leukemia. 2018 Sep 11. doi: 10.1038/s41375-018-0249-z. [Epub ahead of print] No abstract available.

PMID:
30206306
2.

Relationship between CD33 expression, splicing polymorphism, and in vitro cytotoxicity of gemtuzumab ozogamicin and the CD33/CD3 BiTE® AMG 330.

Laszlo GS, Beddoe ME, Godwin CD, Bates OM, Gudgeon CJ, Harrington KH, Walter RB.

Haematologica. 2019 Feb;104(2):e59-e62. doi: 10.3324/haematol.2018.202069. Epub 2018 Aug 16. No abstract available.

3.

Simultaneous multiple interaction T-cell engaging (SMITE) bispecific antibodies overcome bispecific T-cell engager (BiTE) resistance via CD28 co-stimulation.

Correnti CE, Laszlo GS, de van der Schueren WJ, Godwin CD, Bandaranayake A, Busch MA, Gudgeon CJ, Bates OM, Olson JM, Mehlin C, Walter RB.

Leukemia. 2018 May;32(5):1239-1243. doi: 10.1038/s41375-018-0014-3. Epub 2018 Jan 31. No abstract available.

4.

Erratum to: High expression of myocyte enhancer factor 2C (MEF2C) is associated with adverse-risk features and poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group.

Laszlo GS, Alonzo TA, Gudgeon CJ, Harrington KH, Kentsis A, Gerbing RB, Wang YC, Ries RE, Raimondi SC, Hirsch BA, Gamis AS, Meshinchi S, Walter RB.

J Hematol Oncol. 2016 Nov 30;9(1):133. No abstract available.

5.

Expression and functional characterization of CD33 transcript variants in human acute myeloid leukemia.

Laszlo GS, Harrington KH, Gudgeon CJ, Beddoe ME, Fitzgibbon MP, Ries RE, Lamba JK, McIntosh MW, Meshinchi S, Walter RB.

Oncotarget. 2016 Jul 12;7(28):43281-43294. doi: 10.18632/oncotarget.9674.

6.

Characterization of CD33/CD3 Tetravalent Bispecific Tandem Diabodies (TandAbs) for the Treatment of Acute Myeloid Leukemia.

Reusch U, Harrington KH, Gudgeon CJ, Fucek I, Ellwanger K, Weichel M, Knackmuss SH, Zhukovsky EA, Fox JA, Kunkel LA, Guenot J, Walter RB.

Clin Cancer Res. 2016 Dec 1;22(23):5829-5838. Epub 2016 May 17.

7.

High expression of myocyte enhancer factor 2C (MEF2C) is associated with adverse-risk features and poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group.

Laszlo GS, Alonzo TA, Gudgeon CJ, Harrington KH, Kentsis A, Gerbing RB, Wang YC, Ries RE, Raimondi SC, Hirsch BA, Gamis AS, Meshinchi S, Walter RB.

J Hematol Oncol. 2015 Oct 20;8:115. doi: 10.1186/s13045-015-0215-4. Erratum in: J Hematol Oncol. 2016 Nov 30;9(1):133.

8.

The Broad Anti-AML Activity of the CD33/CD3 BiTE Antibody Construct, AMG 330, Is Impacted by Disease Stage and Risk.

Harrington KH, Gudgeon CJ, Laszlo GS, Newhall KJ, Sinclair AM, Frankel SR, Kischel R, Chen G, Walter RB.

PLoS One. 2015 Aug 25;10(8):e0135945. doi: 10.1371/journal.pone.0135945. eCollection 2015.

9.

T-cell ligands modulate the cytolytic activity of the CD33/CD3 BiTE antibody construct, AMG 330.

Laszlo GS, Gudgeon CJ, Harrington KH, Walter RB.

Blood Cancer J. 2015 Aug 21;5:e340. doi: 10.1038/bcj.2015.68.

10.

Multimerin-1 (MMRN1) as Novel Adverse Marker in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group.

Laszlo GS, Alonzo TA, Gudgeon CJ, Harrington KH, Gerbing RB, Wang YC, Ries RE, Raimondi SC, Hirsch BA, Gamis AS, Meshinchi S, Walter RB.

Clin Cancer Res. 2015 Jul 15;21(14):3187-95. doi: 10.1158/1078-0432.CCR-14-2684. Epub 2015 Mar 30.

11.

Heterogeneity of clonal expansion and maturation-linked mutation acquisition in hematopoietic progenitors in human acute myeloid leukemia.

Walter RB, Laszlo GS, Lionberger JM, Pollard JA, Harrington KH, Gudgeon CJ, Othus M, Rafii S, Meshinchi S, Appelbaum FR, Bernstein ID.

Leukemia. 2014 Oct;28(10):1969-77. doi: 10.1038/leu.2014.107. Epub 2014 Mar 18.

12.

High expression of suppressor of cytokine signaling-2 predicts poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group.

Laszlo GS, Ries RE, Gudgeon CJ, Harrington KH, Alonzo TA, Gerbing RB, Raimondi SC, Hirsch BA, Gamis AS, Meshinchi S, Walter RB.

Leuk Lymphoma. 2014 Dec;55(12):2817-21. doi: 10.3109/10428194.2014.893305. Epub 2014 Mar 24.

13.

Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML.

Laszlo GS, Gudgeon CJ, Harrington KH, Dell'Aringa J, Newhall KJ, Means GD, Sinclair AM, Kischel R, Frankel SR, Walter RB.

Blood. 2014 Jan 23;123(4):554-61. doi: 10.1182/blood-2013-09-527044. Epub 2013 Dec 5.

14.

Significance of expression of ITGA5 and its splice variants in acute myeloid leukemia: a report from the Children's Oncology Group.

Walter RB, Laszlo GS, Alonzo TA, Gerbing RB, Levy S, Fitzgibbon MP, Gudgeon CJ, Ries RE, Harrington KH, Raimondi SC, Hirsch BA, Gamis AS, W McIntosh M, Meshinchi S.

Am J Hematol. 2013 Aug;88(8):694-702. doi: 10.1002/ajh.23486. Epub 2013 Jun 20.

15.

AKT signaling as a novel factor associated with in vitro resistance of human AML to gemtuzumab ozogamicin.

Rosen DB, Harrington KH, Cordeiro JA, Leung LY, Putta S, Lacayo N, Laszlo GS, Gudgeon CJ, Hogge DE, Hawtin RE, Cesano A, Walter RB.

PLoS One. 2013;8(1):e53518. doi: 10.1371/journal.pone.0053518. Epub 2013 Jan 8.

16.

High expression of neutrophil elastase predicts improved survival in pediatric acute myeloid leukemia: a report from the Children's Oncology Group.

Gudgeon CJ, Harrington KH, Laszlo GS, Alonzo TA, Gerbing RB, Gamis AS, Raimondi SC, Hirsch BA, Meshinchi S, Walter RB.

Leuk Lymphoma. 2013 Jan;54(1):202-4. doi: 10.3109/10428194.2012.700480. Epub 2012 Jul 9. No abstract available.

Supplemental Content

Loading ...
Support Center